Please assess the completion status of the following clinical trial:

Trial Title: Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Primary FSGS diagnosed by renal biopsy.~2. Urine protein creatinine ratio (UPCR) ≥2.0 mg/mg, serum albumin ≤3.2 g/dL and can be immunosuppressant treatment-naïve, or receiving treatment with steroids.~3. Stable proteinuria, renal function, and BP.~Exclusion Criteria:~1. Clinical or histologic evidence of secondary FSGS.~2. Histologic evidence of collapsing variant FSGS.~3. eGFR as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation of ≤30 mL/minute/1.73 m2 at initial screening assessment or ≤45 mL/minute/1.73 m2 at last qualifying assessment.~4. Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.~5. Current or medical history of:~   * Congenital or acquired immunodeficiency.~  * In the opinion of the Investigator, clinically significant drug or alcohol abuse within 2 years prior to screening.~  * Malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision.~  * Current or past lymphoproliferative disease or previous total lymphoid irradiation.~  * Severe viral infection within 3 months of screening, or known HIV infection. Severe viral infection is defined as active disease requiring antiviral therapy.~  * Active tuberculosis (TB) or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Voclosporin (Type: EXPERIMENTAL): Cohort 1:~Maximum dose of 3 capsules (7.9mg) BID~Cohort 2~Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).